Arrowhead Pharmaceuticals (ARWR) Reaches $3.49 After 3.00% Down Move; Vident Investment Advisory Has Decreased Its Kite Pharma (KITE) Stake

November 14, 2017 - By Winifred Garcia

Vident Investment Advisory Llc decreased Kite Pharma Inc (KITE) stake by 28.66% reported in 2017Q2 SEC filing. Vident Investment Advisory Llc sold 5,147 shares as Kite Pharma Inc (KITE)’s stock rose 29.36%. The Vident Investment Advisory Llc holds 12,813 shares with $1.33M value, down from 17,960 last quarter. Kite Pharma Inc now has $10.28 billion valuation. It is 0.00% or $0 reaching $179.79 per share. It is down 55.47% since November 14, 2016 and is uptrending. It has outperformed by 38.77% the S&P500.

The stock of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is a huge mover today! About 195,018 shares traded. Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has declined 67.27% since November 14, 2016 and is downtrending. It has underperformed by 83.97% the S&P500.The move comes after 8 months negative chart setup for the $260.95M company. It was reported on Nov, 14 by Barchart.com. We have $3.39 PT which if reached, will make NASDAQ:ARWR worth $7.83 million less.

Among 20 analysts covering Kite Pharma (NASDAQ:KITE), 10 have Buy rating, 0 Sell and 10 Hold. Therefore 50% are positive. Kite Pharma had 53 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of Kite Pharma Inc (NASDAQ:KITE) has “Buy” rating given on Monday, November 21 by H.C. Wainwright. As per Monday, August 17, the company rating was maintained by Mizuho. The company was initiated on Thursday, September 3 by FBR Capital. Suntrust Robinson initiated it with “Buy” rating and $70 target in Friday, January 29 report. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Hold” rating by Stifel Nicolaus on Monday, August 28. The stock of Kite Pharma Inc (NASDAQ:KITE) earned “Buy” rating by Canaccord Genuity on Tuesday, June 27. Stifel Nicolaus maintained Kite Pharma Inc (NASDAQ:KITE) on Friday, November 13 with “Buy” rating. As per Thursday, June 8, the company rating was upgraded by BTIG Research. The company was initiated on Thursday, February 25 by Citigroup. The firm has “Neutral” rating given on Tuesday, August 29 by Wedbush.

Vident Investment Advisory Llc increased Nuveen Preferred Securities (JPS) stake by 55,976 shares to 372,469 valued at $3.81M in 2017Q2. It also upped Varian Med Sys Inc (NYSE:VAR) stake by 29,229 shares and now owns 73,257 shares. Exone Co (NASDAQ:XONE) was raised too.

Since June 1, 2017, it had 0 insider buys, and 5 sales for $5.95 million activity. CHAMPSI FARAH had sold 20,450 shares worth $1.84 million on Wednesday, June 14. BUTITTA CYNTHIA M sold 10,000 shares worth $885,491. Shares for $173,880 were sold by Kim Helen Susan. On Wednesday, June 14 the insider Ruchefsky Steven B sold $1.79 million. On Wednesday, June 7 the insider DOUMANI ROY sold $1.27M.

Investors sentiment decreased to 1.24 in Q2 2017. Its down 0.21, from 1.45 in 2017Q1. It dived, as 29 investors sold KITE shares while 60 reduced holdings. 41 funds opened positions while 69 raised stakes. 49.42 million shares or 4.82% more from 47.15 million shares in 2017Q1 were reported. Pub Employees Retirement Association Of Colorado owns 0.01% invested in Kite Pharma Inc (NASDAQ:KITE) for 8,025 shares. Opus Point Prtn Ltd Llc holds 5,915 shares. Nuveen Asset Mngmt Ltd Liability Corporation holds 9,352 shares or 0.01% of its portfolio. State Board Of Administration Of Florida Retirement System owns 24,127 shares. 3,111 are owned by Commonwealth Equity Ser. Cap Rech Global invested in 0.23% or 6.94M shares. Eventide Asset Mngmt Ltd Co reported 85,000 shares stake. Schwab Charles Mngmt has 0.02% invested in Kite Pharma Inc (NASDAQ:KITE). Cap Fund Mngmt Sa stated it has 38,874 shares or 0.03% of all its holdings. Moreover, Viking LP has 0.34% invested in Kite Pharma Inc (NASDAQ:KITE). 476,952 are held by First Tru Advisors L P. Moreover, Nicholas Invest Ptnrs Lp has 0.2% invested in Kite Pharma Inc (NASDAQ:KITE). Ubs Asset Mngmt Americas Incorporated holds 0% or 280,450 shares in its portfolio. Shell Asset Mgmt Company reported 0.02% of its portfolio in Kite Pharma Inc (NASDAQ:KITE). Polar Capital Llp holds 0.5% or 360,000 shares.

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. The company has market cap of $260.95 million. Using a portfolio of ribonucleic acid chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. It currently has negative earnings. The Firm is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins.

Among 6 analysts covering Arrowhead Research Corp (NASDAQ:ARWR), 1 have Buy rating, 0 Sell and 5 Hold. Therefore 17% are positive. Arrowhead Research Corp had 16 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by Cantor Fitzgerald on Wednesday, November 30 to “Hold”. Cantor Fitzgerald initiated Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) rating on Friday, August 19. Cantor Fitzgerald has “Buy” rating and $15 target. Piper Jaffray maintained it with “Hold” rating and $3.0 target in Thursday, September 14 report. The rating was maintained by Jefferies with “Hold” on Thursday, August 3. The stock has “Buy” rating by Chardan Capital Markets on Thursday, November 10. Cantor Fitzgerald maintained the stock with “Hold” rating in Monday, September 25 report. The firm has “Buy” rating by Chardan Capital Markets given on Thursday, May 19. The rating was downgraded by William Blair on Wednesday, November 30 to “Mkt Perform”. William Blair upgraded the shares of ARWR in report on Monday, September 18 to “Outperform” rating. The stock has “Neutral” rating by PiperJaffray on Wednesday, November 30.

Analysts await Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) to report earnings on December, 13. They expect $-0.13 EPS, up 58.06% or $0.18 from last year’s $-0.31 per share. After $-0.07 actual EPS reported by Arrowhead Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 85.71% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>